Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HAILEY FE 1.5/30 vs BLISOVI FE 1.5/30
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Combination estrogen-progestin contraceptive that suppresses gonadotropin release (FSH and LH) from the pituitary, inhibiting ovulation. Additionally, increases viscosity of cervical mucus and alters endometrial receptivity.
Blisovi Fe 1.5/30 is a combination oral contraceptive containing ethinyl estradiol (estrogen) and norethindrone (progestin). It inhibits ovulation via suppression of gonadotropins (FSH and LH). Additionally, it increases cervical mucus viscosity, impeding sperm penetration, and alters endometrial development, reducing implantation likelihood.
Prevention of pregnancy,Acne vulgaris (off-label for females ≥15 years),Irregular menstruation (off-label)
Prevention of pregnancy
One tablet orally once daily for 21 consecutive days, followed by 7 days of placebo tablets.
One tablet orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets (iron-free).
Ethinyl estradiol: terminal half-life ~17-24 hours; norethindrone: terminal half-life ~5-14 hours (mean 11 hours). The clinical significance is that steady-state is reached within 5-7 days.
Ethinyl estradiol: terminal half-life ~17 hours (range 13–27 h) with single dose; for norethindrone: ~8–11 hours. Clinical context: Steady-state achieved within ~7–10 days; contraceptive efficacy maintained with once-daily dosing.
No dosage adjustment required for renal impairment. Use with caution in severe renal impairment due to potential fluid retention.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential for iron accumulation.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age (especially in women over 35) and with heavy smoking (≥15 cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Category X: Contraindicated in pregnancy. First trimester: Increased risk of neural tube defects, cardiovascular anomalies, and limb reduction defects. Second/third trimesters: Associated with fetal adrenal suppression, hepatic dysfunction, and masculinization of female fetuses. Discontinue immediately if pregnancy occurs.
FDA Pregnancy Category X. Use is contraindicated in pregnant women because drospirenone/ethinyl estradiol can cause fetal harm. There is no indication for use in pregnancy. If pregnancy occurs during treatment, the drug should be discontinued immediately. Epidemiologic studies have not revealed an increased risk of birth defects in infants born to women who inadvertently used oral contraceptives early in pregnancy. However, drospirenone is a progestin with antiandrogenic activity, and animal studies have shown teratogenic effects including urogenital tract abnormalities at high doses.
HAILEY FE 1.5/30 is a combination oral contraceptive containing ethinyl estradiol 30 µg and norethindrone 1.5 mg, with iron supplementation (ferrous fumarate 75 mg). The iron component is not part of the contraceptive effect but helps maintain iron stores during menstruation. It is typically taken for 21 active pills followed by 7 placebo pills (containing iron). Administer consistently at the same time daily to maintain hormone levels and minimize breakthrough bleeding. Monitor for elevated blood pressure, thromboembolic events, and hepatic adenoma. Smoking increases cardiovascular risk; avoid in women over 35 who smoke. Efficacy may be reduced with hepatic enzyme-inducing drugs (e.g., rifampin, certain anticonvulsants).
BLISOVI FE 1.5/30 is a combination oral contraceptive containing ethinylestradiol and norethindrone acetate. It is primarily used for contraception and acne treatment. The iron component (ferrous fumarate) is not intended for contraceptive effect but to offset menstrual blood loss. Monitor for thromboembolic events, especially in smokers over 35. Use caution in patients with migraine with aura, hypertension, or liver disease. Drug interactions with rifampin, certain anticonvulsants, and St. John's wort may reduce contraceptive efficacy.
No interactions on record
No interactions on record
HAILEY FE 1.5/30 and BLISOVI FE 1.5/30 are distinct pharmacological agents. HAILEY FE 1.5/30 belongs to the Oral Contraceptive class and is primarily used for Prevention of pregnancyAcne vulgaris (off-label for females ≥15 years)Irregular menstruation (off-label). BLISOVI FE 1.5/30 belongs to the Oral Contraceptive class and is primarily used for Prevention of pregnancy. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. HAILEY FE 1.5/30 carries a safety status of Category C, whereas BLISOVI FE 1.5/30 safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Ethinyl estradiol: primarily metabolized by CYP3A4 via hydroxylation; undergoes first-pass metabolism in the liver and gut wall. Norethindrone: primarily metabolized via reduction followed by glucuronide conjugation; some involvement of CYP3A4.
Ethinyl estradiol is metabolized primarily via CYP3A4; norethindrone is metabolized via reduction and conjugation, with some involvement of CYP3A4.
Ethinyl estradiol is primarily excreted renally (40-45%) and via bile/feces (45-55%). Norethindrone is excreted 50-60% renally and 30-40% fecally.
Renal: ~60% (ethinyl estradiol metabolites as glucuronide/sulfate conjugates, norethindrone metabolites). Fecal: ~40% (biliary excretion of conjugates, with some enterohepatic recirculation).
Ethinyl estradiol: ~97-98% bound to albumin; norethindrone: ~95% bound to albumin and sex hormone-binding globulin (SHBG).
Ethinyl estradiol: ~97% bound to albumin (specifically to albumin, with some binding to SHBG). Norethindrone: ~61% bound to albumin, ~36% to SHBG. Iron: >99% bound to transferrin and ferritin. Folic acid: ~50–60% bound to plasma proteins (mainly albumin).
Ethinyl estradiol: ~2-4 L/kg; norethindrone: ~2-4 L/kg. Reflects extensive tissue distribution.
Ethinyl estradiol: Vd ~2.7–4.8 L/kg (large, reflecting extensive tissue distribution). Norethindrone: Vd ~3.6–4.3 L/kg. Clinical meaning: large Vd indicates extensive extravascular binding (e.g., fat stores, steroid receptors). Iron: mainly in erythrocytes and reticuloendothelial system; Vd not typically reported. Folic acid: total body folate ~500–20,000 µg, with Vd ~0.6 L/kg (reflects distribution into tissues).
Ethinyl estradiol: 40-50% due to first-pass metabolism; norethindrone: 50-70% due to first-pass metabolism.
Oral ethinyl estradiol: ~38–48% (first-pass metabolism). Norethindrone: ~64% (high first-pass). Folic acid: ~76–93% (dose-dependent; reduced when taken with food). Iron (ferrous fumarate): ~10–20% (varies with iron stores; increased in deficiency).
Contraindicated in acute hepatitis, severe cirrhosis (Child-Pugh C), or liver tumors. For mild hepatic impairment (Child-Pugh A), no adjustment; use with caution.
Contraindicated in severe hepatic impairment (Child-Pugh class C). Use with caution in mild to moderate hepatic impairment; monitor liver function.
Not indicated for premenarchal girls. For postmenarchal adolescents, same dosing as adults.
Not indicated for use in pediatric females before menarche. Safety and efficacy in adolescents have not been established; use is generally not recommended.
Not indicated for postmenopausal women due to higher risk of thromboembolic events and lack of efficacy for contraception in this population.
No specific dose adjustment for geriatric use. Consider increased risk of thromboembolic disorders and monitor accordingly.
Cigarette smoking increases the risk of serious cardiovascular events from oral contraceptive use. The risk increases with age and with heavy smoking (≥15 cigarettes per day). Women over 35 who smoke should not use this product.
No significant food interactions. Grapefruit juice may increase ethinyl estradiol levels but effect is not clinically significant; no restriction. Iron absorption may be enhanced by vitamin C (e.g., citrus); avoid taking with dairy or antacids that reduce iron absorption, separate by at least 2 hours if needed.
Food does not significantly affect absorption of the hormonal components. Grapefruit juice may inhibit metabolism and increase estrogen levels; avoid large amounts. No specific dietary restrictions. Iron tablets may cause gastrointestinal upset; taking with food may help.
Excreted in breast milk in low amounts (estrogen M/P ratio ~0.2; progestin M/P ~0.3). Theoretical risk of reduced milk production and infant jaundice. Use only if benefits outweigh risks; consider alternative contraception.
Small amounts of contraceptive steroids have been identified in breast milk, with about 0.02% of the maternal dose of ethinyl estradiol transferred to the infant via milk. The M/P ratio for drospirenone is approximately 0.4–0.6. Combination oral contraceptives may reduce milk production and composition, and their use during breastfeeding is generally not recommended until weaning or at least 6 months postpartum if the infant is fully nursing. Alternative contraception methods are preferred during lactation.
Contraindicated in pregnancy. No indication for use; pharmacokinetic changes (increased clearance, protein binding changes) are irrelevant as use is prohibited.
There are no recommended dose adjustments for use during pregnancy because the drug is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, decreased protein binding, enhanced clearance) can reduce steroid hormone levels, potentially diminishing efficacy if used inadvertently. Therefore, if pregnancy occurs, discontinue the drug; no dose adjustment is applicable as the drug should not be used.
Take one tablet daily at the same time each day, even if you do not have sex.,The first 21 pills are active hormones; the last 7 pills (green) contain iron and are placebos.,If you miss a pill, follow the package instructions: take the missed pill as soon as remembered, and use backup contraception if you miss more than one.,Common side effects include nausea, breast tenderness, and breakthrough bleeding, especially in the first few months.,Smoking while on this pill increases risk of serious cardiovascular events; do not smoke.,Contact your healthcare provider if you experience leg pain, chest pain, sudden severe headache, or visual changes.,HAILEY FE does not protect against HIV or other sexually transmitted infections; use condoms for protection.,Inform your doctor of all medications you take, including over-the-counter drugs and supplements.,If you have severe vomiting or diarrhea, use additional contraception.,Store at room temperature away from moisture and heat.
Take one tablet daily at the same time each day. The first 21 tablets are active hormones; the last 7 are iron tablets.,If you miss a dose, refer to the package instructions. Missing pills increases risk of pregnancy.,Do not smoke while taking this medication, especially if over 35 years old, due to increased risk of blood clots.,Contact your healthcare provider if you experience severe headaches, chest pain, leg pain, vision changes, or jaundice.,This medication does not protect against HIV or other sexually transmitted infections.,Inform your doctor about all medications you are taking, including over-the-counter drugs and supplements.,The iron tablets may cause black or dark stools; this is harmless.,If you experience persistent vomiting or diarrhea, use additional contraception.